Home Featured Page 115

Featured

Latest

Psilocybin for Cocaine Use Disorder: Peter Hendricks on a Trial Ten Years in the Making

Pα+ Psychedelic Bulletin #224: Reactions to Trump’s Psychedelics Executive Order, and What Comes Next; Pre-EO, DEA Poured Cold Water on Right to Try

God, Gabon, and Government: W. Bryan Hubbard on Ibogaine, the Executive Order, and What Comes Next

The Optimisation Problem: What Bryan Johnson’s 5-MeO-DMT Experiment Reveals About Psychedelics Going Mainstream

Field Trip Health & Wellness to Close Clinics in 5 Locations

Silo Pharma Announces Positive Results from IND-Enabling Study of SP-26 for...

FILAMENT HEALTH ANNOUNCES FDA APPROVAL OF PHASE II CLINICAL TRIAL STUDYING...

CORRECTION — BetterLife Closes $1,857,143 of Private Placement

PT398 – Lost Civilizations, DMT Entities, & Altered States of Consciousness...

Mindset Pharma To Defend Against Lawsuit Filed By Reunion Neurosciences

Clearmind Medicine Appoints Professor Henry R. Kranzler, M.D., to Scientific Advisory...

BetterLife Closes $1,857,143 of Private Placement

Reunion Neuroscience Files Lawsuit Against Mindset Pharma

BetterLife Files Amended and Restated Offering Document for Offering of Units

EDITOR PICKS

Psilocybin for Cocaine Use Disorder: Peter Hendricks on a Trial Ten...

Pα+ Psychedelic Bulletin #224: Reactions to Trump’s Psychedelics Executive Order, and...

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.